Owing to its role in regulating metabolism, AMPK has been considered a promising pharmacological target for treating diseases such as diabetes, obesity, cardiometabolic diseases and cancer [7]. Here, PRKAA1 is linked to obesity due to melanocortin 4 receptor deficiency.